Tew - PDFSEARCH.IO - Document Search Engine

Tew
Results: 140

#	Item
51	PDF Document Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:09 ViiV Healthcare Intel Viiv Prescription Drug User Fee Act Shionogi Integrase inhibitor Food and Drug Administration Integrase Pharmaceutical sciences Pharmacology Clinical research
52	Shionogi & Co., Ltd. Shionogi Signs Agreement with Denmark on International Industry-Academic Collaboration Initiatives Osaka, Japan, April 1, 2011- Shionogi & Co., Ltd. (Head Office: Osaka; CEO and Representative Dire Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:24 Research and development Europe Shionogi Denmark
53	Microsoft Word - 20130218_FDA Priority Review Designation for DTG_E_Final Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:24 Pharmacology Integrase inhibitors HIV/AIDS Intel Viiv Shionogi ViiV Healthcare Integrase New Drug Application Prescription Drug User Fee Act Food and Drug Administration Pharmaceutical sciences Medicine
54	Microsoft Word - OspemifeneNDA20120426 Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:21 Pain Shionogi Rosuvastatin Dyspareunia Doripenem Menopause Atrophy Medicine Anatomy Chemistry
55	January 13, 2010 Shionogi & Co., Ltd. Shionogi Receives Marketing and Manufacturing Approval of a Novel Anti-viral Drug for Influenza, “RAPIACTA 300mg Bag for Intravenous Drip Infusion” and Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:20 Neuraminidase inhibitors Acetamides Guanidines Peramivir Medicine Dosage forms Shionogi Intravenous therapy Pharmacology Alcohols Chemistry
56	Shionogi & Co., Ltd. Shionogi Receives an Approval for an Additional Indication for Pediatric Use of RAPIACTA®, a Novel Anti-viral Drug for Influenza Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:23 Neuraminidase inhibitors Alcohols Dosage forms Acetamides Guanidines Peramivir Influenza Intravenous therapy FluMist Medicine Pharmacology Chemistry
57	Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor Phase III Treatment-naïve and Treatment-experienced Trials Underway for S/GSK1349572 (‘572) Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:21 Health Medicine Integrase inhibitors GlaxoSmithKline ViiV Healthcare Lamivudine Pfizer Integrase Raltegravir Organofluorides Chemistry HIV/AIDS
58	Shionogi & Co., Ltd. Shionogi and GlaxoSmithKline to collaborate on the research, development and commercialization of novel antibiotics targeting drug-resistant Gram-negative bacteria Osaka, Japan, October 28, 2010 ‐ Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:18 Antibiotics Moraxellaceae Multiple drug resistance Pharmacology Bacterial diseases Acinetobacter Shionogi Antibacterial Pathogenic bacteria Bacteria Microbiology Biology
59	Shionogi Files an Application for an Anti-hypertension Drug “S”, a Combination of Irbesartan and Trichlormethiazide Osaka, Japan, July 30, Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CE Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:23 Organochlorides Lactams Antihypertensive drug Irbesartan Angiotensin II receptor antagonist Shionogi Diuretic Hypertension Thiazide Chemistry Organic chemistry Tetrazoles
60	PDF Document Add to Reading List Source URL: shionogi616.tew-staging.com Language: English - Date: 2014-11-03 11:26:24 Thiazides Diuretics Tetrazoles Lactams Irbesartan Trichlormethiazide Angiotensin II receptor antagonist Antihypertensive drug Hypertension Chemistry Organic chemistry Organochlorides

UPDATE